📰 Study Treatment News
Study Treatment News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study Treatment. Real-time updates on events, politics, business and more.
May 31, 2023
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release.TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase®
May 31, 2023
TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development
May 10, 2023
Theralase Provides Update on Phase II Bladder Cancer Study
April 26, 2023
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
April 3, 2023
03.04.2023 - Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors ...
May 29, 2021
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage…
April 27, 2021
Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Companys Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non...